Showing 741 - 760 results of 8,891 for search 'significant ((((((step decrease) OR (teer decrease))) OR (we decrease))) OR (mean decrease))', query time: 0.28s Refine Results
  1. 741
  2. 742
  3. 743

    The RehaGait® system. by Johanna Rydja (12300797)

    Published 2025
    “…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”
  4. 744

    Flow chart of included patients and dropouts. by Johanna Rydja (12300797)

    Published 2025
    “…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”
  5. 745

    Dataset of the analyzed data. by Johanna Rydja (12300797)

    Published 2025
    “…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”
  6. 746
  7. 747

    Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

    Published 2024
    “…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”
  8. 748
  9. 749
  10. 750
  11. 751
  12. 752
  13. 753

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  14. 754

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  15. 755

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  16. 756
  17. 757
  18. 758

    Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

    Published 2025
    “…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …”
  19. 759
  20. 760